Table 1 The demographic and disease characteristics of the participants
Variables | Mean ± SD or n (%) |
|---|---|
Age (range) | 34.29 ± 13.65 (18–70) |
Gender | |
Females | 116 (61.7) |
Males | 72 (38.3) |
Disease | |
RA | 76 (40.4) |
SLE | 58 (30.9) |
Psoriatic arthritis | 16 (8.5) |
Behcet’s disease | 14 (7.4) |
AS | 8 (4.3) |
Reactive arthritis | 8 (4.3) |
Systemic sclerosis | 8 (4.3) |
Disease duration (range) | 6.73 ± 5.589 (1–30) |
Steroid | |
Use | 134 (71.3) |
Do not use | 54 (28.7) |
Conventional DMARD | |
Use | 160 (85.1) |
Do not use | 28 (14.9) |
Steroid dose (prednisolone) | |
≤ 5 | 96 (71.64) |
> 5–20 | 34 (25.37) |
> 20 | 4 (2.98) |
Biologics | |
Use | 18 (9.6) |
Do not use | 170 (90.4) |
COVID-19 vaccination | |
Vaccinated | 104 (55.3) |
Non-vaccinated | 84 (44.7) |
Worker | |
Working | 126 (67) |
Non-working | 62 (33) |
Educational level | |
Low | 27 (14.4) |
Medium | 33 (17.6) |
High | 128 (68.1) |
Socioeconomic level | |
Low | 25 (13.3) |
Medium | 56 (29.8) |
High | 107 (56.9) |
Disease functional impact | |
Mild | 20 (10.6) |
Moderate | 86 (45.7) |
Severe | 82 (43.6) |
Main source of knowledge | |
Television | 30 (16) |
Internet | 92 (48.9) |
Specialists | 66 (35.1) |
Compliance before the pandemic | |
Compliant | 160 (85.1) |
Previous confirmed COVID-19 | |
Confirmed infection | 30 (15.9) |
Severe COVID-19 infection (needed hospitalization or ICU) | |
Severe infection | 20 (66.6) |